Esketamine for depression: all studies (page 22)

Exploring Esketamine's Therapeutic Role for Perinatal Depression via TASK-1 Tandem Pore Potassium Channels.

ACS Chemical Neuroscience July 29, 2025 Lin Zhu, Ji Chen, Yuan Liu et al. 1 citation

This research focuses on the promising use of esketamine in perinatal depression, a widespread disorder impacting postpartum women's mental health. Despite esketamine's known rapid antidepressant effects, its precise mechanisms are not fully understood. This study integrates clinical and preclinical approaches to explore esketamine's efficacy in treating perinatal depression and its actions...

DOI: 10.1021/acschemneuro.5c00535 Full text Synaptic plasticity Neuroinflammation New approach Lowers depression scores +8

Effectiveness of repeated Esketamine nasal spray administration on anhedonic symptoms in treatment-resistant bipolar and unipolar depression: A secondary analysis from the REAL-ESK study group.

Psychiatry Research July 26, 2025 Giacomo D’andrea, Clara Cavallotto, Mauro Pettorruso et al. 16 citations

INTRODUCTION Anhedonia, defined as the diminished ability to experience or anticipate pleasure, is a core symptom of major depressive disorder (MDD) and bipolar depression (BD), and associated with depression severity, suicidality and poor treatment outcomes. Conventional antidepressants demonstrate limited efficacy against anhedonia. Esketamine nasal spray (ESK-NS) - a novel NMDA receptor...

DOI: 10.1016/j.psychres.2025.116655 Full text

Outcomes of patients receiving interventional psychiatric procedures in a large integrated healthcare system.

Psychiatry Research July 19, 2025 Kevin J Li, Natalie E Slama, Ingrid L Chen et al. 2 citations

Interventional psychiatric procedures (IPPs) such as electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), and ketamine intravenous treatments (KIT) are widely used for treatment resistant depression (TRD), but we lack studies of their real-world impact compared to standard outpatient medication management (MM). Longitudinal electronic health records of 22,481 patients in a...

DOI: 10.1016/j.psychres.2025.116647 Full text Esketamine Mdd Major depressive disorder Electroconvulsive therapy +12

Insomnia and Esketamine Add-On Therapy to Antidepressant Therapy in Patients with Treatment-Resistant Depression-A Pilot Study.

Pharmaceuticals (Basel, Switzerland) July 19, 2025 Daniel Szawarnoga, Joanna Fojcik, Michał Górski et al. 1 citation

Background: Insomnia, as one of the most common sleep disorders, is a significant health problem, especially among patients suffering from drug-resistant depression. Problems related to the quality of sleep in that population can significantly affect the effectiveness of treatment and quality of life, which is why it is necessary to search for effective therapeutic interventions in this area....

DOI: 10.3390/ph18071066 Full text Esketamine Treatment-resistant depression S-ketamine Insomnia +5

Does BMI matter when treating depression with esketamine? A retrospective analysis of real-world data.

Journal of Affective Disorders July 15, 2025 Mina Ansari, Taeho Greg Rhee, Mia C Santucci et al. 4 citations

Intranasal (IN) esketamine was approved as a therapy for treatment-resistant depression in March 2019. There continues to be interest in the field to better understand factors associated with response to treatment. The aim of the current study is to assess the association between BMI and response to esketamine. A retrospective analysis was conducted on all patients treated with intranasal...

DOI: 10.1016/j.jad.2025.03.198 Full text Esketamine Treatment-resistant depression Psychiatric treatment Depression treatment +4

When mood and time align: nasal esketamine reduces lived time disturbances in treatment-resistant depression.

International journal of psychiatry in clinical practice July 10, 2025 Stefan Jerotić, Milica Nestorovic, Janko Nešić et al. 3 citations

These two cases highlight the utility of a focused, structured clinical phenomenological interview in measuring treatment effectiveness in subjective experience. Two male patients, aged 35 and 27, of Serbian ethnicity with treatment-resistant depression were treated with nasal esketamine, with clinical progress monitored using both the Montgomery-Åsberg Depression Rating Scale (MADRS) and the...

DOI: 10.1080/13651501.2025.2528692 Full text Esketamine Phenomenology Treatment-resistant depression Depression treatment +15

Antidepressant effects of esketamine are associated with functional connectivity in the hippocampal subregion: A resting state magnetic resonance study.

Neuroscience July 8, 2025 Xiang Liu, Yumeng Liu, Jun Tu et al. 2 citations

We aimed to investigate the relationship between changes in resting-state functional connectivity in a subregion of the hippocampus and the antidepressant effects of esketamine as well as to identify potential neuroimaging markers of the treatment outcomes. Twenty-nine patients with major depressive disorder (MDD) received six intravenous infusions of esketamine. All patients completed the...

DOI: 10.1016/j.neuroscience.2025.07.016 Full text Esketamine Major depressive disorder Mdd Functional connection +14

S-ketamine ameliorates post-stroke depression in mice via attenuation of neuroinflammation, synaptic restoration, and BDNF pathway activation.

Biochemical and Biophysical Research Communications July 8, 2025 Jiaxin Tian, Yanhong Xie, Sen Ye et al. 6 citations

The available therapeutic options for post-stroke depression patients are limited. Although SSRIs are the most commonly prescribed antidepressants, their slow onset of action and the higher risk of adverse effects or contraindications have led to an urgent need to develop fast-acting and highly specific antidepressants tailored to the needs of PSD patients. Therefore, ketamine has drawn...

DOI: 10.1016/j.bbrc.2025.151965 Full text S-ketamine Neuroinflammation Post-stroke depression psd Synaptic function +5

Esketamine disinhibits brain networks in depression: Evidence from oscillatory and aperiodic activity.

Progress in neuro-psychopharmacology & biological psychiatry July 5, 2025 Verina Guirguis, Sanvi Korsapathy, Francesca Pupillo et al. 6 citations

Nasal Esketamine is a rapid-acting intervention for depression, hypothesized to exert its effects through cortical disinhibition. However, the spatio-temporal dynamics of brain network activity and their relationship to the subjective drug experience following Esketamine administration remain elusive. This observational study aims to delineate brain network-level effects of Esketamine by...

DOI: 10.1016/j.pnpbp.2025.111438 Full text Major depressive disorder Aperiodic exponent Brain oscillations Esketamine treatment +9

Plasma esketamine and noresketamine levels and antidepressant response with oral esketamine treatment.

European Journal of Pharmacology July 5, 2025 Jolien K E Veraart, Sanne Y Smith-Apeldoorn, Jeanine Kamphuis et al. 2 citations

Oral esketamine has relatively low and variable bioavailability, which may complicate broader use as an antidepressant. This study aimed to investigate associations between different pharmacokinetic outcomes and change in depressive symptoms following oral esketamine administration in patients with treatment-resistant depression. Understanding such associations may inform dosing and...

DOI: 10.1016/j.ejphar.2025.177470 Full text Mdd Spravato Clinical depression Esketamine ketamine +5